HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside ChinaGlobeNewsWire · 4 days ago
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The ProductSeeking Alpha · 4 days ago
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to AnalystsDefense World · Oct 16, 2026
ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill24/7 Wall Street · Oct 3, 2026 HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $0.15 | $0.05 | Miss |
| Jul 2, 2026 | -$0.36 | $0.05 | Beat |
| Mar 5, 2026 | $2.50 | $0.00 | Miss |
| Aug 7, 2025 | $1.46 | $2.60 | Beat |
| Jul 2, 2025 | -$0.32 | $1.35 | Beat |
| Mar 19, 2025 | $0.04 | $0.07 | Beat |